###begin article-title 0
Scaffold attachment factor B1 (SAFB1) heterozygosity does not influence Wnt-1 or DMBA-induced tumorigenesis
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 170 173 170 173 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 159 163 <span type="species:ncbi:10090">mice</span>
###xml 324 328 <span type="species:ncbi:10090">mice</span>
###xml 408 412 <span type="species:ncbi:10090">mice</span>
###xml 516 520 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
Scaffold Attachment Factor B1 (SAFB1) is a multifunctional protein which has been implicated in breast cancer previously. We recently generated SAFB1 knockout mice (SAFB1-/-), but pleiotropic phenotypes including high lethality, dwarfism associated with low IGF-I levels, and infertility and subfertility in male and female mice, respectively, do not allow for straightforward tumorigenesis studies in these mice. Therefore, we asked whether SAFB1 heterozygosity would influence tumor development and progression in MMTV-Wnt-1 oncomice or DMBA induced tumorigenicity, in a manner consistent with haploinsufficiency of the remaining allele.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 23 27 23 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 97 100 97 100 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 113 116 113 116 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 133 137 133 137 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 216 220 216 220 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 228 232 228 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 39 43 <span type="species:ncbi:10090">mice</span>
###xml 54 58 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 77 81 <span type="species:ncbi:10090">mice</span>
###xml 137 141 <span type="species:ncbi:10090">mice</span>
###xml 239 243 <span type="species:ncbi:10090">mice</span>
We crossed female SAFB1+/- (C57B6/129) mice with male MMTV-Wnt-1 (C57B6/SJL) mice to obtain SAFB1+/+/Wnt-1, SAFB1+/-/Wnt-1, and SAFB1+/- mice. For the chemical induced tumorigenesis study we treated 8 weeks old SAFB1+/- and SAFB+/+ BALB/c mice with 1 mg DMBA once per week for 6 weeks. Animals were monitored for tumor incidence and tumor growth. Tumors were characterized by performing H&E, and by staining for markers of proliferation and apoptosis.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 85 88 85 88 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 104 107 104 107 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 150 154 150 154 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 163 166 163 166 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 479 482 479 482 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 510 513 510 513 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 591 595 591 595 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 114 118 <span type="species:ncbi:10090">mice</span>
###xml 166 170 <span type="species:ncbi:10090">mice</span>
###xml 595 599 <span type="species:ncbi:10090">mice</span>
We did not detect significant differences in tumor incidence and growth between SAFB1+/+/Wnt-1 and SAFB1+/-/Wnt-1 mice, and between DMBA-treated SAFB1+/+ and SAFB1+/-mice. Histological evaluation of tumors showed that SAFB1 heterozygosity did not lead to changes in proliferation or apoptosis. There were, however, significant differences in the distribution of tumor histologies with an increase in papillary and cribriform tumors, and a decrease in squamous tumors in the SAFB1+/-/Wnt-1 compared to the SAFB1+/+/Wnt-1 tumors. Of note, DMBA treatment resulted in shortened survival of SAFB1+/- mice compared to their wildtype littermates, however this trend did not reach statistical significance.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
Our data show that SAFB1 heterozygosity does not influence Wnt-1 or DMBA-induced mammary tumorigenesis.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 152 153 152 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 287 288 279 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 595 596 587 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 706 715 698 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 729 730 721 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1027 1028 1019 1020 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 981 989 <span type="species:ncbi:9606">patients</span>
Scaffold Attachment Factor B1 (SAFB1) is a multifunctional protein that is involved in RNA processing, transcriptional regulation, and stress response [1]. SAFB1 has previously been implicated in breast tumorigenesis. SAFB1 functions as an estrogen receptor alpha (ERalpha) corepressor [2], and its overexpression in cultured cells leads to growth inhibition. Importantly, SAFB1 mutations have been identified in microdissected breast tumors but not in the normal adjacent tissue, and SAFB1's chromosomal locus displays extremely high loss of heterozygocity LOH (78%) in invasive breast cancer [3]. There is no significant different in LOH frequencies between ER-positive and ER-negative tumors, and other in vitro observations [4] suggest that SAFB1 could exert its effect on tumorigenesis, at least in part, through ER-independent mechanisms. This is further supported by our recent observation that loss of SAFB1/SAFB1 is associated with worse overall survival of breast cancer patients, but does affect Tamoxifen response [5]. Collectively, these data suggest that SAFB1 loss affects breast tumorigenesis in ER-dependent and independent manner.
###end p 11
###begin p 12
###xml 39 42 39 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 50 51 50 51 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 270 274 270 274 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 434 438 434 438 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 550 554 550 554 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 44 48 <span type="species:ncbi:10090">mice</span>
###xml 274 278 <span type="species:ncbi:10090">mice</span>
###xml 438 442 <span type="species:ncbi:10090">mice</span>
###xml 554 558 <span type="species:ncbi:10090">mice</span>
###xml 673 677 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
We have generated SAFB1 knockout (SAFB1-/-) mice [6] which are characterized by high prenatal and neonatal lethality, growth retardation associated with low serum insulin-like growth factor I (IGF-I) levels, as well as female subfertility and male infertility. The SAFB1-/- mice that are born alive succumb to frailty, often associated with infections, and die of unknown reasons at an early age. These pleiotropic phenotypes of SAFB1-/- mice make tumorigenesis studies difficult to perform, and we therefore asked whether partial SAFB1 loss in SAFB1+/- mice would influence mammary tumor formation or progression. Therefore, we used two different tumor models; transgenic MMTV-Wnt-1 oncomice, and a chemical carcinogen model, in which tumors were induced with 7, 12-dimethylbenz (a) anthracene (DMBA).
###end p 12
###begin p 13
###xml 103 104 103 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 258 259 258 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 260 262 260 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 400 402 400 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 540 542 540 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 637 639 637 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 805 807 805 807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 225 230 <span type="species:ncbi:9606">human</span>
###xml 291 316 <span type="species:ncbi:11757">mouse mammary tumor virus</span>
###xml 318 322 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 370 376 <span type="species:ncbi:10090">murine</span>
###xml 515 519 <span type="species:ncbi:10090">mice</span>
###xml 534 538 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 558 562 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 587 591 <span type="species:ncbi:10090">mice</span>
###xml 652 656 <span type="species:ncbi:10090">mice</span>
Genes of the Wnt family function in the regulation of growth and differentiation of the mammary gland [7]. Mutation or deregulation of several components and transcriptional targets of the Wnt signaling have been observed in human cancers, including breast [8-12]. Mammary tumors induced by mouse mammary tumor virus (MMTV) infection have revealed oncogenes involved in murine mammary tumorigenesis [13], and Wnt-1 was the first proto-oncogene discovered as a gene frequently activated in mammary tumors arising in mice infected with MMTV [14]. About 50% of MMTV-Wnt-1 transgenic female mice develop mammary tumors by 5-6 months of age [15], and these mice have therefore frequently been used to study the effect of potential tumor suppressor or oncogenes on mammary gland tumorigenesis (for review, see [16]).
###end p 13
###begin p 14
###xml 130 132 130 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 174 180 174 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al </italic>
###xml 181 183 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 304 306 304 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 318 320 318 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 298 302 <span type="species:ncbi:10116">rats</span>
###xml 312 316 <span type="species:ncbi:10090">mice</span>
DMBA is a prototypical polycyclic aromatic hydrocarbon (PAHs) with carcinogenic and immunosuppressive effects in various species [17]. Since it was first reported by Huggins et al [18], DMBA-induced mammary tumors have been widely used as a spontaneous cancer model in laboratory animals including rats [19] and mice [20].
###end p 14
###begin p 15
###xml 314 318 314 318 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 318 322 <span type="species:ncbi:10090">mice</span>
In this study, we have analyzed the effect of partial SAFB1 loss on Wnt-1 and DMBA-induced tumorigenesis. Here show that SAFB1 heterozygosity does not affect tumor incidence and tumor growth. However, we observed changes in the Wnt-1 tumor histopathology, and a trend towards shorter survival in DMBA-treated SAFB1+/- mice.
###end p 15
###begin title 16
Results
###end title 16
###begin title 17
###xml 46 50 46 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 50 54 <span type="species:ncbi:10090">mice</span>
SAFB1 protein expression is decreased in SAFB1+/- mice
###end title 17
###begin p 18
###xml 68 72 68 72 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 240 244 240 244 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 267 271 267 271 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 284 286 284 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 417 420 417 420 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 451 454 451 454 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 72 76 <span type="species:ncbi:10090">mice</span>
###xml 244 248 <span type="species:ncbi:10090">mice</span>
###xml 271 275 <span type="species:ncbi:10090">mice</span>
First, we set out to confirm decreased SAFB1 protein levels in SAFB1+/- mice using a number of different tissues, including testes, spleen, lung, and mammary gland (Figure 1A). Quantification revealed an average decrease of 42% in the SAFB1+/- mice, compared to SAFB1+/+ mice (Figure 1B). A similar decrease was observed in the tumors, where we detected an average of 53% decrease of SAFB1 protein expression in SAFB1+/-/Wnt-1 tumors compared to SAFB1+/+/Wnt-1 tumors (data not shown).
###end p 18
###begin p 19
###xml 46 50 46 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 59 63 59 63 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 0 67 0 67 <bold xmlns:xlink="http://www.w3.org/1999/xlink">SAFB1 protein expression in tissues from SAFB1<sup>+/+ </sup>and SAFB1<sup>+/- </sup>mice</bold>
###xml 411 415 408 412 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 489 493 486 490 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 63 67 <span type="species:ncbi:10090">mice</span>
###xml 235 239 <span type="species:ncbi:10090">mice</span>
###xml 336 340 <span type="species:ncbi:10090">mice</span>
###xml 493 497 <span type="species:ncbi:10090">mice</span>
SAFB1 protein expression in tissues from SAFB1+/+ and SAFB1+/- mice. A) A representative immunoblot using lysates from different tissues, and antibodies, as indicated. beta-actin was used as a loading control. Blots are shown are from mice on a C57Bl/6J x 129/Sv genetic background, but is also representative of difference observed in mice on a BALB/c background. B) Percentage of SAFB1 protein levels in SAFB1+/- tissues, corrected for b-actin levels, relative to protein levels in SAFB1+/+ mice.
###end p 19
###begin title 20
Tumor-free survival and tumor growth
###end title 20
###begin title 21
###xml 12 16 <span type="species:ncbi:10090">mice</span>
SAFB1-Wnt-1 mice
###end title 21
###begin p 22
###xml 23 27 23 27 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 174 177 174 177 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 193 196 193 196 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 227 229 227 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 249 251 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 334 337 334 337 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 374 377 374 377 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 474 477 474 477 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 502 505 502 505 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 27 31 <span type="species:ncbi:10090">mice</span>
###xml 42 46 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 53 68 <span type="species:ncbi:10090">transgenic mice</span>
###xml 92 96 <span type="species:ncbi:10090">mice</span>
###xml 384 388 <span type="species:ncbi:10090">mice</span>
###xml 526 530 <span type="species:ncbi:10090">mice</span>
We crossed female SAFB1+/- mice with male MMTV-Wnt-1 transgenic mice to obtain experimental mice. There was no significant difference in time to tumor formation between SAFB1+/+/Wnt-1 and SAFB1+/-/Wnt-1 in both females (Figure 2A) and males (Figure 2B). The median time to tumor formation (MTTF) was 31 weeks (n = 31) for female SAFB1+/+/Wnt-1, and 34 weeks for female SAFB1+/-/Wnt-1 mice (n = 29). Similarly, we did not detect a significant difference in MTTF between SAFB1+/+/Wnt-1 (n = 23) and SAFB1+/-/Wnt-1 (n = 25) male mice. Thus, partial SAFB1 loss does not accelerate the formation, or alter the incidence of Wnt-1 induced mammary tumors.
###end p 22
###begin p 23
###xml 0 61 0 61 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effect of SAFB1 heterozygosity on Wnt-1-induced tumorigenesis</bold>
###xml 124 127 124 127 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 143 146 143 146 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 326 330 326 330 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 338 342 338 342 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 431 432 431 432 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 153 157 <span type="species:ncbi:10090">mice</span>
###xml 285 300 <span type="species:ncbi:10090">transgenic mice</span>
Effect of SAFB1 heterozygosity on Wnt-1-induced tumorigenesis. Kaplan-Meier survival curves of female (A) and male (B) SAFB1+/+/Wnt-1 and SAFB1+/-/Wnt-1 mice. Ages in weeks were recorded at the time of first tumor observation. C) and D) Growth rates of tumors in female and male Wnt-1 transgenic mice, respectively, on a SAFB1+/+ or SAFB1+/- background. The graphs represent time in weeks for tumor growth from detection to 1000 mm3, with error bars representing SEM.
###end p 23
###begin p 24
###xml 219 222 219 222 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 230 232 230 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 313 315 313 315 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 358 359 358 359 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
###xml 412 414 412 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
###xml 442 444 442 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2D</xref>
###xml 505 508 505 508 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 524 527 524 527 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 378 382 <span type="species:ncbi:10090">mice</span>
###xml 429 433 <span type="species:ncbi:10090">mice</span>
Since tumor incidence was not significantly affected by partial SAFB1 loss, we asked whether loss of one SAFB1 allele would result in accelerated rates of tumor growth, as has been described for other models such as p21+/-/Wnt-1 [21]. We therefore analyzed length of time necessary for tumors to grow from < 50 mm3 (time of detection by palpation) to 1000 mm3. Tumors in female mice grew slightly faster (Figure 2C) than in male mice (Figure 2D), however, there was no significant difference between SAFB1+/+/Wnt-1 and SAFB1+/-/Wnt-1 animals in either group.
###end p 24
###begin p 25
###xml 46 48 46 48 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 246 249 246 249 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 280 283 280 283 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 12 16 <span type="species:ncbi:10090">mice</span>
###xml 290 294 <span type="species:ncbi:10090">mice</span>
###xml 424 428 <span type="species:ncbi:10090">mice</span>
Since Wnt-1 mice can develop lung metastases [22], we also asked whether partial loss of SAFB1 would affect the metastatic potential in our animals. We microscopically analyzed H&E-stained lung tissue, and detected metastases in 4 out of 13 SAFB1+/+/Wnt-1, and in 3 out of 8 SAFB1+/-/Wnt-1 mice which was not statistically different. Thus, SAFB1 heterozygosity did not affect the development of lung metastases in the Wnt-1 mice.
###end p 25
###begin p 26
###xml 173 175 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 176 178 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 362 364 362 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 387 391 387 391 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 487 488 487 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 572 575 572 575 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 590 593 590 593 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 391 395 <span type="species:ncbi:10090">mice</span>
###xml 600 604 <span type="species:ncbi:10090">mice</span>
IGF-I plays an important role in cell proliferation, differentiation, and apoptosis, and it has also been linked to malignant transformation and breast cancer pathogenesis [23-26]. Numerous studies have shown that a reduction of circulating IGF-I is associated with a decrease in carcinogen and oncogenes induced cancer (in particular, breast and colon cancer) [27]. Interestingly, SAFB1-/- mice are characterized by growth retardation, which was correlated with low serum IGF-I levels [6]. However, we did not detect a significant difference in IGF-I levels between SAFB1+/+/Wnt-1 or SAFB1+/-/Wnt-1 mice (data not shown), and can thus exclude the possibility that decreased IGF-I levels could mask an effect of SAFB1 heterozygosity on tumorigenesis.
###end p 26
###begin title 27
DMBA treatment
###end title 27
###begin p 28
###xml 146 150 146 150 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 162 165 162 165 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 211 215 211 215 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 226 229 226 229 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 92 96 <span type="species:ncbi:10090">mice</span>
###xml 132 136 <span type="species:ncbi:10090">mice</span>
###xml 198 202 <span type="species:ncbi:10090">mice</span>
We next analyzed the effect of SAFB1 heterozygosity on DMBA induced tumorigenesis in BALB/c mice. This study comprised of 67 female mice (34 SAFB1+/+ and 33 SAFB1+/-) in the treatment group, and 15 mice (8 SAFB1+/+ and 7 SAFB1+/-) in the vehicle treated control group.
###end p 28
###begin p 29
###xml 229 233 229 233 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 250 254 250 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 276 278 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 84 88 <span type="species:ncbi:10090">mice</span>
###xml 263 267 <span type="species:ncbi:10090">mice</span>
We first analysed the development of mammary tumors after DMBA treatment. Seventeen mice (28.4%) of the DMBA treated animals developed mammary tumors, however there was no significant difference in tumor development between SAFB1+/+ (n = 9) and SAFB1+/- (n = 10) mice (Figure 3A).
###end p 29
###begin p 30
###xml 0 60 0 60 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Effect of SAFB1 heterozygosity on DMBA induced tumorigenesis</bold>
###xml 190 194 190 194 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 203 207 203 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 207 211 <span type="species:ncbi:10090">mice</span>
Effect of SAFB1 heterozygosity on DMBA induced tumorigenesis. Kaplan-Meier survival curves of mammary gland tumor free (A), all tumor free (B), and overall survival (C) in DMBA-treated SAFB1+/+ and SAFB1+/- mice. Time in weeks were recorded from the first day of DMBA treatment to the time of first tumor observation (A, B), and death or sacrifice of animals due to comorbidity (C).
###end p 30
###begin p 31
###xml 230 234 230 234 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 246 249 246 249 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 352 356 352 356 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 365 369 365 369 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 382 384 382 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 369 373 <span type="species:ncbi:10090">mice</span>
In addition to the mammary gland tumors, animals also developed tumors in other organs including skin, blood, intestine, liver, and lung. A total of 34 animals (50.7%) developed at least one tumor during the study period (17 SAFB1+/+ and 17 SAFB1+/-), but again there was no significant difference in tumor free survival (from all tumors) between SAFB1+/+ and SAFB1+/- mice (Figure 3B).
###end p 31
###begin p 32
###xml 256 260 256 260 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 308 311 308 311 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 335 339 335 339 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 352 354 352 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3C</xref>
###xml 553 557 553 557 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 568 571 568 571 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 612 616 612 616 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 1044 1048 1044 1048 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 260 264 <span type="species:ncbi:10090">mice</span>
###xml 339 343 <span type="species:ncbi:10090">mice</span>
###xml 540 544 <span type="species:ncbi:10090">mice</span>
###xml 588 592 <span type="species:ncbi:10090">mice</span>
###xml 616 620 <span type="species:ncbi:10090">mice</span>
###xml 1048 1052 <span type="species:ncbi:10090">mice</span>
Next we analyzed the overall survival (OS) of the DMBA treated animals. The data captured for OS included death as a result of tumorigenesis, and sacrifice due to co-morbidity of unknown reasons. Interestingly, there was a trend for shorter OS in the SAFB1+/- mice; the median survival was 40 weeks for SAFB1+/+, and 35 weeks for SAFB1+/- mice (Figure 3C). To investigate whether this could be due to differential effects of DMBA on the hematopoietic system, we performed complete blood count (CBC) and blood smear test for 15 DMBA treated mice (7 SAFB1+/+ and 8 SAFB1+/-), and 2 control mice. Although one SAFB1+/- mice developed B-cell lymphoma, all other blood parameters including red blood cell count, white blood cell count, platelet count, amount of hemoglobin, mean corpuscular volume, mean corpuscular hemoglobin, and mean corpuscular hemoglobin concentration, were not significantly different between both genotypes (data not shown), suggesting that the observed trend was unlikely due to a defect in hematopoietic system in the SAFB1+/- mice. In summary, SAFB1 heterozygosity did not lead to statistically significant effects on DMBA-induced tumorigenesis.
###end p 32
###begin title 33
Histological analysis of tumors
###end title 33
###begin title 34
SAFB1-Wnt-1 tumor
###end title 34
###begin p 35
###xml 284 286 284 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 498 501 498 501 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 586 589 586 589 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
We next asked whether partial SAFB1 loss would lead to changes in the histopathology of the Wnt-1 tumors. H&E staining revealed that tumors of both SAFB1 genotypes were well-differentiated, and mainly characterized by three tumor patterns: papillary, cribriform, and squamous (Figure 4A). There was a small difference in the pattern distribution between the two genotypes: while the papillary, cribriform, and squamous pattern represented 45-50%, 40-45%, and <5% distribution respectively, in SAFB1+/+/Wnt-1 tumors, they represented 70%, 25% and <5% distribution, respectively, in SAFB1+/-/Wnt-1 tumors (p = 0.01).
###end p 35
###begin p 36
###xml 0 67 0 67 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Histological evaluation of Wnt-1 tumors of different SAFB1 genotype</bold>
###xml 82 85 82 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 101 104 101 104 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 111 115 <span type="species:ncbi:10090">mice</span>
###xml 292 296 <span type="species:ncbi:10090">mice</span>
###xml 545 549 <span type="species:ncbi:10090">mice</span>
Histological evaluation of Wnt-1 tumors of different SAFB1 genotype. A) Both SAFB1+/+/Wnt-1 and SAFB1+/-/Wnt-1 mice exhibit papillary, cribriform and squamous tumor type patterns. Representative pictures are shown (magnification 20x). B) Tumors found in the female (n = 10 per each genotype) mice were sectioned and stained with phospho H3 antibody. Representative pictures are shown (magnification 40x). The graph represents the quantification of phospho H3-positive cells/field. Error bars represent SEM. C). Wnt-1 tumours found in the female mice were sectioned and stained with caspase 3 antibody (n = 10 per each genotype). Representative pictures are shown (magnification 40x). The graph shows quantification of caspase 3-positive cells/field, with error bars representing SEM (p = 0.0742). Bars represent 100 mum.
###end p 36
###begin p 37
###xml 105 108 105 108 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 124 127 124 127 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 386 388 386 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 441 444 441 444 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 460 463 460 463 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 696 699 696 699 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 791 793 791 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4C</xref>
###xml 470 474 <span type="species:ncbi:10090">mice</span>
###xml 706 710 <span type="species:ncbi:10090">mice</span>
Next, we set out to determine whether there was a difference in proliferation and apoptosis between SAFB1+/+/Wnt-1 and SAFB1+/-/Wnt-1 tumors. Therefore, we stained the tumors using BrdU antibody to detect the percentage of cells in S phase, and using phosphorylated H3 (phospho H3) antibody to detect mitotic cells. We did not observe significant changes in the mitotic figures (Figure 4B), and in number of BrdU-positive cells between SAFB1+/+/Wnt-1 and SAFB1+/-/Wnt-1 mice (data not shown). Similarly, we did not detect a significant difference in rates of apoptosis, as measured by IHC using antibodies for cleaved caspase 3, although there was a trend towards decreased apoptosis in the SAFB1+/-/Wnt-1 mice (p = 0.0742 as calculated by unpaired t test, n = 10 per each genotype) (Figure 4C). Together, these data show that partial SAFB1 loss does not affect proliferative and apoptotic rates in Wnt-1 tumors.
###end p 37
###begin title 38
DMBA induced tumors
###end title 38
###begin p 39
###xml 275 277 275 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 434 436 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
Finally, we determined whether SAFB1 heterozygosity would lead to changes in the histopathology of the DMBA-induced mammary tumors. H&E staining revealed similar histopathology in both groups, in that the tumors mostly contained keratinized squamous epithelial cells (Figure 5A). We also did not detect any significant difference in the percentage of BrdU-positive cells (data not shown), and cleaved caspase-3 positive cells (Figure 5B) between the two SAFB1 genotypes. We thus conclude that SAFB1 heterozygosity did not affect proliferative and apoptotic rates in DMBA-induced tumors.
###end p 39
###begin p 40
###xml 0 74 0 74 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Histological evaluation of DMBA induced tumors of different SAFB1 genotype</bold>
###xml 89 93 89 93 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 102 106 102 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 106 110 <span type="species:ncbi:10090">mice</span>
Histological evaluation of DMBA induced tumors of different SAFB1 genotype. A) Both SAFB1+/+ and SAFB1+/- mice mostly exhibit squamous tumor type patterns. Representative pictures are shown (magnification 20x). B) DMBA-induced tumors were stained with cleaved caspase 3 antibody. Representative pictures are shown (magnification 40x). Bars represent 100 mum for A and 50 mum for B.
###end p 40
###begin title 41
Discussion
###end title 41
###begin p 42
###xml 51 58 51 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
To better understand SAFB1's role in tumorigenesis in vivo, we have analyzed the effect of partial SAFB1 loss on Wnt-1 and DMBA induced tumorigenesis. Our results show that SAFB1 heterozygosity does not accelerate incidence or growth of either Wnt-1 or DMBA-induced tumors.
###end p 42
###begin p 43
###xml 284 286 284 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 722 724 722 724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 765 767 765 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 875 877 875 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 941 947 941 947 <sup xmlns:xlink="http://www.w3.org/1999/xlink">INK4a </sup>
###xml 954 958 954 958 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ARF </sup>
###xml 1016 1018 1016 1018 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1300 1305 1300 1305 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Kip1 </sup>
###xml 1389 1391 1389 1391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1510 1512 1510 1512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1648 1650 1648 1650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1872 1874 1872 1874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1935 1937 1935 1937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1953 1955 1953 1955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1333 1337 <span type="species:ncbi:10090">mice</span>
###xml 1412 1416 <span type="species:ncbi:10090">mice</span>
###xml 1526 1530 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 1537 1552 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1642 1646 <span type="species:ncbi:10090">mice</span>
###xml 1925 1929 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 1943 1947 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 1957 1961 <span type="species:ncbi:10090">mice</span>
The absence of an effect could suggest that SAFB1 heterozygosity is not sufficient to cause an increase in tumorigenesis. Indeed, the classical Knudson's two-hit hypothesis states that tumor suppressor genes are recessive, and that both alleles must be inactivated for tumorigenesis [28]. This model was based on the repeated observation that familial cancers often result from the initial germline mutation of one allele of a tumor suppressor gene, followed by subsequent somatic mutation or loss of the second allele. Consistent with this, there are numerous studies showing that loss of a single allele of a tumor suppressor gene does not increase tumorigenesis. For example, partial p53 loss did not accelerate Wnt-1 [29] or DMBA-induced mammary tumorigenesis [30]. Similarly, Brca1 and Brca2 heterozygosity did not affect tumor formation induced by the Wnt-1 transgene [16], and partial deletion of the INK4a locus that encodes both p16INK4a and p19ARF did not result in increased DMBA-induced tumor formation [31]. However, there are also many reports where heterozygosity results in significantly increased tumorigenicity, thus demonstrating haploinsufficiency of the remaining allele. For example, inactivation of a single allele of the gene encoding the cyclin-dependent kinase inhibitor p27Kip1 was sufficient to sensitize mice to radiation and carcinogen-induced tumorigenesis [32]. Dmp1-heterozygote mice treated with DMBA or ionizing radiation accelerated tumorigenesis compared to the wild type [33]. Similarly, MMTV-Wnt-1 transgenic mice which are heterozygous for PTEN developed mammary tumors earlier than the PTEN wild type mice [22]. At this point of time, we cannot exclude the possibility that partial SAFB1 loss would influence the tumorigenicity in other tumor models. For example, as discussed above, partial p53 loss did not cooperate with Wnt-1 [29], however, it did accelerate tumor development in MMTV-Ras [34] and MMTV-Myc [35] mice models.
###end p 43
###begin p 44
###xml 135 144 135 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 145 146 145 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 147 149 147 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 155 163 155 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 164 165 164 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 516 520 516 520 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 528 530 528 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
Our study specifically addressed the question of the effect of SAFB1 heterozygosity in hormone-independent mammary gland tumors. Both, in vitro [4,36] and in vivo [5] data suggest that SAFB1 has ER-independent activities. Unpublished studies from our group showed that SAFB1 heterozygosity results in increased ER activity in MEFs, both in the absence and presence of ligand, and thus future studies should address potential effects of SAFB1 heterozygosity in development of hormone-dependent tumors, such as the p53-/- tumors [37].
###end p 44
###begin p 45
###xml 159 163 159 163 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 189 193 189 193 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 588 591 588 591 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 607 610 607 610 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 795 797 795 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 798 800 798 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 1021 1024 1021 1024 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 163 167 <span type="species:ncbi:10090">mice</span>
###xml 193 197 <span type="species:ncbi:10090">mice</span>
Two interesting observations from this study warrant further discussion. First, we observed a non-significant trend towards a shorter overall survival of SAFB1+/- mice compared to the SAFB1+/+ mice after DMBA treatment. We did not find any obvious defects in the haematopoietic system but the increase in lethality could be due to increased tumor development in other organs, or defects in the immune system, resulting from the partial loss of SAFB1. Second, we observed subtle differences in the histological distribution pattern of the papillary and cribriform tumor types between SAFB1+/+/Wnt-1 and SAFB1+/-/Wnt-1 tumors. The Wnt pathway is known to influence cell fate determination, stem cells renewal, and expansion of progenitor cells in a number of tissues, including the mammary gland [38-40]. Wnt1-ransformed progenitor cells might differentiate into multiple cells types, resulting in tumor heterogeneity. A role of SAFB1 affects in this function of Wnt-1 could explain the altered histology of tumors in SAFB1+/-/Wnt-1 tumors.
###end p 45
###begin p 46
In summary, we have shown that partial SAFB1 loss does not cooperate with Wnt-1 or DMBA induced tumorigenesis. Future studies using conditional deletion of both alleles will address the question of whether complete loss of SAFB1 expression results in increased mammary gland tumorigenesis.
###end p 46
###begin title 47
Methods
###end title 47
###begin title 48
Animal models
###end title 48
###begin p 49
###xml 172 173 172 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 174 176 174 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 379 382 379 382 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 395 398 395 398 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 415 418 415 418 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 604 614 604 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ad libitum</italic>
###xml 0 4 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 11 26 <span type="species:ncbi:10090">transgenic mice</span>
###xml 190 194 <span type="species:ncbi:10090">mice</span>
###xml 446 450 <span type="species:ncbi:10090">mice</span>
MMTV-Wnt-1 transgenic mice (a kind gift from Dr. Larry Donehower, Baylor College of Medicine) and those that carry a mutant allele of SAFB1 have been described previously [6,15]. Male Wnt-1 mice (on a mixed SJL and C57BL/6 background) were crossed with SAFB1 heterozygous females (on a mixed C57BL/6J and 129Sv background) to generate the three genotypes used in our study: SAFB1+/+/Wnt-1, SAFB1+/-/Wnt-1, and SAFB1+/-. For DMBA analysis we used mice on a BALB/c background. All animals were maintained in a pathogen-free facility at Baylor College of Medicine, and fed a diet of standard food and water ad libitum. All procedures were approved by the BCM Institutional Animal Care and Use Committee.
###end p 49
###begin title 50
Genotyping and Immunoblotting
###end title 50
###begin p 51
The genotypes were determined by isolating tail DNA and performing PCR. Primers used to detect the intact SAFB1 gene (5'-TAT TAT CAT CTG CAT TCA CCA GTT G-3' and 5'-TCT GTG CTC CCA TCA TCT GTC TTC TTG-3') generate a 715 bp PCR product. Primers used to detect LacZ (5'-CTG CTG ATG AAG CAG AAC AAC TTT A-3' and 5'-GAC AGA TTT GAT CCA GCG ATA CAG-3') generate a PCR product of 306 bp. Primers used to detect Wnt-1 transgene (5'-GAA CTT GCT TCT CTT CTC ATA GCC-3' and 5'-CCA CAC AGG CAT AGA GTG TCT GC-3') generate a 350 bp PCR product.
###end p 51
###begin p 52
###xml 176 179 176 179 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 188 192 188 192 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 470 471 470 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 905 909 902 906 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 939 943 936 940 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 58 62 <span type="species:ncbi:10090">mice</span>
###xml 85 89 <span type="species:ncbi:10090">mice</span>
###xml 192 196 <span type="species:ncbi:10090">mice</span>
###xml 555 566 <span type="species:ncbi:3704">horseradish</span>
###xml 600 605 <span type="species:ncbi:10090">mouse</span>
###xml 614 620 <span type="species:ncbi:9986">rabbit</span>
###xml 909 913 <span type="species:ncbi:10090">mice</span>
###xml 943 947 <span type="species:ncbi:10090">mice</span>
To confirm decreased SAFB1 protein levels of heterozygous mice compared to wild type mice, snap-frozen testes, spleen, lung, kidney, uterus and mammary gland tissues from SAFB1+/+and SAFB1+/- mice were crushed, lysed in 5% sodium dodecyl sulfate (SDS), and sonicated. Proteins were resolved by SDS polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane. After blocking (PBS and 0.1% Tween 20 (PBST) + 5% milk), membranes were probed with SAFB1 [6] and beta-actin (Sigma) antibodies. Protein-antibody complexes were detected using horseradish peroxidase-linked secondary anti-mouse or anti-rabbit (Amersham Biosciences), and the signal was developed using enhanced chemiluminescence (Pierce) according to manufacturer's instructions. Bands were quantitated using FluorChem 8000 (Alpha Inotech Corp.) and averaged the percentages of SAFB1 expression in all analyzed tissues of SAFB1+/- mice with respect to the SAFB1+/+ mice
###end p 52
###begin title 53
Tumorigenesis study
###end title 53
###begin p 54
###xml 64 68 <span type="species:ncbi:10090">mice</span>
###xml 151 157 <span type="species:ncbi:3635">cotton</span>
###xml 245 249 <span type="species:ncbi:10090">mice</span>
###xml 259 265 <span type="species:ncbi:3635">cotton</span>
For DMBA induced tumorigenesis, 8 week old virgin female BALB/c mice were treated with 1 mg/week DMBA (Sigma-Aldrich Inc, St. Louis, MO), dissolved in cotton seed oil (Sigma-Aldrich Inc, St. Louis, MO) by gavage for 6 consecutive weeks. Control mice received cotton seed oil only.
###end p 54
###begin p 55
###xml 360 362 360 362 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 1075 1079 1069 1073 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 73 77 <span type="species:ncbi:10090">mice</span>
###xml 303 307 <span type="species:ncbi:10090">Mice</span>
###xml 651 655 <span type="species:ncbi:10090">Mice</span>
###xml 1022 1026 <span type="species:ncbi:10090">mice</span>
###xml 1095 1099 <span type="species:ncbi:10090">mice</span>
After weaning (Wnt tumor), or one week after DMBA treatment (DMBA tumor) mice were monitored 3 times/week for tumor formation by visual inspection and palpation. Tumors were measured with a calliper and volume was calculated according to the formula (W*W*L)/2, where W is the width and L is the length. Mice where euthanized when tumor volume reached > 1000 mm3 or general health conditions deteriorated due to unknown reasons. All animals that did not develop palpable tumors were harvested at the end of the study period (50-52 weeks after DMBA treatment). Necropsies were performed to determine incidence of non-palpable tumors or blood disorders. Mice were injected with 100 mg/kg BrdU 2 hr prior to sacrifice for subsequent measurements of proliferation. At the time of sacrifice, tumors and lungs were removed. Part of the tumors was used for paraffin-embedding and the remaining part was frozen at -80degreesC. Blood samples were obtained from some of the animals and analyzed for hematological parameters. Control mice without the Wnt-1 transgene of both groups SAFB1+/- female and male mice were monitored for up to 18 months. In the Wnt-1 study, both breeding and non-breeding males and only virgin females were used for data collection.
###end p 55
###begin title 56
Histological analysis
###end title 56
###begin p 57
###xml 310 316 <span type="species:ncbi:9986">rabbit</span>
Lung and tumor cross-sections were fixed in fresh 4% paraformaldehyde overnight, and stored in 70% ethanol until embedding. Samples were paraffin embedded, sectioned, and H&E stained using standard protocols, by the Breast Center Pathology Core at BCM. For the immunohistochemical (IHC) staining, we have used rabbit anti-caspase 3 antibody (Cell Signalling) to measure apoptosis and BrdU In Situ detection kit II (BD Pharmingen) to analyze proliferation. In the Wnt study we have additionally stained with anti-phosphorylated H3 (Upstate) to measure mitotic index of the tumors.
###end p 57
###begin p 58
###xml 233 236 233 236 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 245 249 245 249 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 220 224 <span type="species:ncbi:10090">mice</span>
Three photographs from different areas of the tumors were taken per each slide and the percentage of these apoptotic and proliferations marker-positive cells was calculated. Blood samples were taken from 17 DMBA treated mice (7 SAFB1+/+, 8 SAFB1+/- and 2 control) by cardiac puncture. Haematological analyses were carried out on the Advia 120 (Bayer Diagnostics) automated hematology analyzer, and blood smears were evaluated for abnormalities.
###end p 58
###begin title 59
Statistical Analysis
###end title 59
###begin p 60
For all statistical tests, p </= 0.05 was considered statistically significant. The time from birth (Wnt-1 tumors) or from the first DMBA treatment to the time of tumor appearance and death were subjected to Kaplan-Meier analysis.
###end p 60
###begin title 61
Abbreviations
###end title 61
###begin p 62
###xml 218 222 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 224 229 <span type="species:ncbi:10090">Mouse</span>
The abbreviation used are: DMBA: 7,12-dimethylbenz(a)anthracene; BrdU: Bromodeoxyuridine; ERalpha: Estrogen Receptor alpha; H&E: Hematoxylin and Eosin; LOH: Loss of Heterozygosity; IGF-I: Insulin-Like Growth Factor-I; MMTV: Mouse Mammary Tumor Virus; OS: Overall Survival; PAH: Polycyclic Aromatic Hydrocarbon; SAFB: Scaffold Attachment Factor B; SEM: Standard Error of the Mean.
###end p 62
###begin title 63
Competing interests
###end title 63
###begin p 64
The authors declare that they have no competing interests.
###end p 64
###begin title 65
Authors' contributions
###end title 65
###begin p 66
BK planned and performed DMBA study and data analysis, and prepared the draft version of the manuscript. KD planned and performed Wnt-1 study, data analysis, and prepared the draft version of the manuscript. OB performed the animal experiments, AL, YL, ML and DM participated in the study design and in the scientific discussion. SO participated in the conception, supervision, and coordination of the study, and manuscript preparation. All authors have read and approved the final version of the manuscript.
###end p 66
###begin title 67
Acknowledgements
###end title 67
###begin p 68
###xml 93 108 <span type="species:ncbi:10090">transgenic mice</span>
We are grateful to Dr. Larry Donehower (Baylor College of Medicine) for providing male Wnt-1 transgenic mice, Dr. Syed Mohsin (Baylor College of Medicine) for help with analyzing the tumors and helpful discussion, the staff at the Breast Center Pathology Core (Baylor College of Medicine) for outstanding service. We would like to thank Dr. Robert Dearth, Mr. Ryan Hartmaier, Ms. Tao Wang, and Dr. Susan G Hilsenbeck (Baylor College of Medicine) for statistical analysis, and Yang Li and Winfred Frazier (Baylor College of Medicine) for help with analyzing BrdU and ER staining. This work was supported by NIH P01 CA030195 and CA92713 (SO). KD was supported by the Department of Defense Breast Cancer Predoctoral Traineeship Award W81XWH-04-1-0355.
###end p 68
###begin article-title 69
Scaffold attachment factors SAFB1 and SAFB2: Innocent bystanders or critical players in breast tumorigenesis?
###end article-title 69
###begin article-title 70
Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation
###end article-title 70
###begin article-title 71
###xml 60 65 <span type="species:ncbi:9606">human</span>
High rates of loss of heterozygosity on chromosome 19p13 in human breast cancer
###end article-title 71
###begin article-title 72
###xml 103 108 <span type="species:ncbi:9606">human</span>
HET/SAF-B overexpression causes growth arrest and multinuclearity and is associated with aneuploidy in human breast cancer
###end article-title 72
###begin article-title 73
###xml 67 75 <span type="species:ncbi:9606">patients</span>
Low SAFB levels are associated with worse outcome in breast cancer patients
###end article-title 73
###begin article-title 74
Scaffold attachment factor B1 functions in development, growth, and reproduction
###end article-title 74
###begin article-title 75
Wnt signaling in breast cancer: have we come full circle?
###end article-title 75
###begin article-title 76
###xml 66 71 <span type="species:ncbi:9606">human</span>
An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells
###end article-title 76
###begin article-title 77
Wnt signalling and the mechanistic basis of tumour development
###end article-title 77
###begin article-title 78
###xml 56 61 <span type="species:ncbi:9606">human</span>
The significance of the Wnt pathway in the pathology of human cancers
###end article-title 78
###begin article-title 79
The Wnt signaling pathway and its role in tumor development
###end article-title 79
###begin article-title 80
Wnt signaling and cancer
###end article-title 80
###begin article-title 81
PTEN deficiency: a role in mammary carcinogenesis
###end article-title 81
###begin article-title 82
###xml 27 52 <span type="species:ncbi:11757">mouse mammary tumor virus</span>
Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome
###end article-title 82
###begin article-title 83
###xml 32 47 <span type="species:ncbi:10090">transgenic mice</span>
###xml 132 136 <span type="species:ncbi:10090">mice</span>
Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice
###end article-title 83
###begin article-title 84
###xml 7 11 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 18 33 <span type="species:ncbi:10090">transgenic mice</span>
Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer
###end article-title 84
###begin article-title 85
Cytochrome P450 1B1 is required for 7,12-dimethylbenz(a)-anthracene (DMBA) induced spleen cell immunotoxicity
###end article-title 85
###begin article-title 86
Mammary cancer induced by a single feeding of polymucular hydrocarbons, and its suppression
###end article-title 86
###begin article-title 87
###xml 0 3 <span type="species:ncbi:10116">Rat</span>
Rat models of premalignant breast disease
###end article-title 87
###begin article-title 88
###xml 63 68 <span type="species:ncbi:10090">mouse</span>
Chemical carcinogen-induced tumorigenesis in parous, involuted mouse mammary glands
###end article-title 88
###begin article-title 89
###xml 20 25 <span type="species:ncbi:10090">mouse</span>
Absence of p53 in a mouse mammary tumor model promotes tumor cell proliferation without affecting apoptosis
###end article-title 89
###begin article-title 90
###xml 54 58 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 65 80 <span type="species:ncbi:10090">transgenic mice</span>
Deficiency of Pten accelerates mammary oncogenesis in MMTV-Wnt-1 transgenic mice
###end article-title 90
###begin article-title 91
Evidence for a link between IGF-I and cancer
###end article-title 91
###begin article-title 92
The insulin-like growth factor system and cancer
###end article-title 92
###begin article-title 93
The IGF system and breast cancer
###end article-title 93
###begin article-title 94
Crosstalk between the insulin-like growth factors and estrogens in breast cancer
###end article-title 94
###begin article-title 95
Clinical relevance of systemic and local IGF-I
###end article-title 95
###begin article-title 96
Chasing the cancer demon
###end article-title 96
###begin article-title 97
###xml 61 76 <span type="species:ncbi:10090">transgenic mice</span>
Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability
###end article-title 97
###begin article-title 98
###xml 111 115 <span type="species:ncbi:10090">mice</span>
Infrequent p53 mutations in 7,12-dimethylbenz[a]anthracene-induced mammary tumors in BALB/c and p53 hemizygous mice
###end article-title 98
###begin article-title 99
Role of the INK4a locus in tumor suppression and cell mortality
###end article-title 99
###begin article-title 100
###xml 4 10 <span type="species:ncbi:10090">murine</span>
The murine gene p27Kip1 is haplo-insufficient for tumour suppression
###end article-title 100
###begin article-title 101
Dmp1 is haplo-insufficient for tumor suppression and modifies the frequencies of Arf and p53 mutations in Myc-induced lymphomas
###end article-title 101
###begin article-title 102
###xml 85 89 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 94 98 <span type="species:ncbi:10090">mice</span>
Increased tumor proliferation and genomic instability without decreased apoptosis in MMTV-ras mice deficient in p53
###end article-title 102
###begin article-title 103
###xml 4 8 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 116 131 <span type="species:ncbi:10090">transgenic mice</span>
The MMTV/c-myc transgene and p53 null alleles collaborate to induce T-cell lymphomas, but not mammary carcinomas in transgenic mice
###end article-title 103
###begin article-title 104
Disruption of scaffold attachment factor B1 leads to TBX2 up-regulation, lack of p19ARF induction, lack of senescence, and cell immortalization
###end article-title 104
###begin article-title 105
Hormone dependence in premalignant mammary progression
###end article-title 105
###begin article-title 106
Stem cells in the skin: waste not, Wnt not
###end article-title 106
###begin article-title 107
Mammary stem cells, self-renewal pathways, and carcinogenesis
###end article-title 107
###begin article-title 108
The canonical Wnt pathway in early mammalian embryogenesis and stem cell maintenance/differentiation
###end article-title 108

